Best Oncology Companies in Stockholm County, Sweden

Developer of personalized immunotherapeutics for oncology, autoimmune and inflammatory diseases. The company has TCR-modified T-cell therapies against multiple antigen classes, tumours, genetic mutations, and viruses that cause cancer. The proprietary Immuno-technology platform for its target discovery, validation, and product development.

Developer of therapeutics to treat cancers, inflammation, and autoimmune diseases. It offers one-carbon metabolism pathway-based therapeutics that target DNA repair and DNA damage response for the treatment of BRCA mutated cancer with PARP inhibitors.

Developer of immunotherapies for cancer and autoimmune therapies. It offers Seqitope an antibody epitope mapping method, Opti-mAb for CAR-T cells, and bispecific antibodies development for cancer treatment.

Funding rounds

• Feb 2026Seed—
• Oct 2024Seed$684.9K

Founders & team

Maria KnudsenCEO

Investors

KI Holding, Northislet, Phase2Phase

Tech stack

AngularCart FunctionalityCore-JsGoogle Font ApiHstsMicrosoft 365

Developer of radiopharmaceuticals for the treatment of cancer. The company has pTTL cell therapy product, which targets neoantigens by using proprietary PIOR and patented EpiTCer technologies, targeting neoantigens using immune cells from cancer patients as starting material.

Funding rounds

• Feb 2026Series A$9.8M
• Mar 2024Seed$473K
• Nov 2023Grant (prize money)$2.6M
• 2023Grant (prize money)$8.9M

Founders & team

Samuel SvenssonCEO

Investors

EIC Fund, Okomera, Eureka, Europa, Sciety, Northislet

Tech stack

Animate.CssCloudflareCloudflare Bot ManagementCookie NoticeCore-JsElementor

Developer of antibody mimetic and protein based drug for the treatment of multiple diseases. Its proprietary technology platforms are Affibody molecules is used for developing antibody mimetics monoclonal antibodies and antibody fragments. The leading candidate of the company is for prevention of Alzheimers disease, autoimmune diseases, and psoriasis, along with diagnostic imaging program for metastatic breast cancer.

Provider of liquid biopsy-based molecular diagnostics for cancer detection. The company offers a liquid biopsy platform for the detection and monitoring of the disease. The test is based on the measurement of various biomarkers. The test uses machine learning algorithms to generate a score against cancer-type specific signatures. The test is primarily meant for renal cell carcinoma. The test helps in early detection, differential diagnosis, and monitoring or prediction of treatment response, replacing or complementing medical imaging.

Funding rounds

• Jun 2022Series A$21M
• May 2022Grant (prize money)$53.8K
• Dec 2019Seed$6.9M
• May 2019Grant (prize money)$2.6M

Founders & team

Karl BergmanCEO

Investors

Industrifonden, Sciety, Nina Capital, Chalmers Ventures, Norrsken VC, European Innovation Council

Tech stack

WebflowJsdelivrJqueryGoogle Hosted LibrariesGoogle Font ApiOpen Graph

InDex Pharmaceuticals develops drugs for the treatment of ulcerative colitis. It offers Kappaproct, a DNA-based immunomodulatory sequence medication (TLR Agonists) that provides a local anti-inflammatory effect leading to healing of the mucosa and improvement of clinical symptoms for patients with severe ulcerative colitis; and DiBiCol, a diagnostic test that differentiates between ulcerative colitis and Crohn’s disease, the two major forms of inflammatory bowel disease.

SciBase AB has developed a point of care device Nevisense for the detection of malignant melanoma. It is based on Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. The company conducted a pivotal study in 2012 including 1,951 patients and 2,416 lesions at 22 sites in Europe and US.

Funding rounds

• May 2021Post IPO—
• Dec 2013Series B$18M
• Feb 2005Series A$4.3M

Founders & team

Stig OllmarFounder

Investors

CapMan, SEB, Van Herk Groep, ÖstVäst Advisory AB, SEB Venture Capital, Fouriertransform

Tech stack

All In One SeoBootstrapContact Form 7Font AwesomeGoogle AnalyticsGoogle Maps

Cancer profiling tool for precision oncology through liquid biopsy test. It offer CellMate a next generation circulating tumor test for the detection of cancer by analysing of blood and saliva samples to healthcare providers and individual consumers.

Funding rounds

• Jun 2023Series A$1.8M
• Jul 2021Grant (prize money)$1.2M
• Dec 2019Series A$2.4M

Founders & team

Pelle RedareEntrepreneur & Co-founder

Investors

Europa, Uppsala Innovation Centre, EIT Health

Developer of cell-based immunotherapy for the treatment of cancer. The company’s platform technology and leading autologous drug candidate, CellProtect, has ideal properties for targeting cancer. The product pipeline inlcudes ACP - 001 and ISA-HC-NK​.

Funding rounds

• Mar 2022Series B$13.9M

Founders & team

Johan LiwingCEO

Investors

Flerie

Developing therapies targeting DNA Damage Response to cure cancer and inflammation. Their solution, OXC-101, is a mitotic MTH1 inhibitor that prevents cancer cells from repairing DNA and oxygen damage, leading to cell death. It also has OXC-201 that blocks the onset of both inflammation and fibrosis.

Funding rounds

• Feb 2023Grant (prize money)$2.7M
• Jan 2016Grant (prize money)$60K

Founders & team

Ulrika BerglundCEO

Investors

Europa

Axelar is developing anti-cancer treatments that target the insulin-like growth factor-1 receptor signalling pathway. The company’s lead drug candidate, AXL1717, is an orally bioavailable small molecule that targets the IGF-1R signalling pathway. The company has completed a randomised, controlled, multicenter, multinational Phase II study on non-small cell lung cancer. The company aims to partner with a pharmaceutical company to complete the clinical program and bring a product to market.